Glenn Leemans, Fluidda’s Chief Operative Officer (COO), was interviewed at the ERS 2019 conference in Madrid. In this interview, Glenn explains why Fluidda’s proprietary functional respiratory imaging (FRI) technique can de-risk clinical trials on cure or care of lung diseases in all phases from pre-clinical to phase IV.
This makes the trials shorter, smaller and thus more cost efficient. FRI parameters can reduce the number of patients required in clinical trials up to sixteen times compared with spirometry while maintaining adequate power and statistical significance.
FRI amplifies the treatment signal and reduces the noise associated with traditional spirometry endpoints.
Categorised in: Conferences / November 27, 2019 9:00 am /Tags: Benefits, ERS, FRI